Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA). It belongs to the group of serpins (serine protease inhibitors). Elevated levels of PAI-1 are associated with poor prognosis in many types of cancer (1-5).
Suitable for use in ELISA, Western Blot, Immunohistochemistry, and Neutralization. Other applications have not been tested.
Optimal dilutions to be determined by the researcher.
RPMI 1640 with 10% fetal calf serum
NCI-Ag 4/1 myeloma cells with spleen cells from Balb/c mice.
Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
|Partially purified human PAI-1|
|Purified by Protein A/G affinity chromatography. |
|Supplied as a liquid in PBS, pH 7.4, 15mM sodium azide.|
|Recognizes human PAI-1. Binds to an epitope consisting of amino acids 110-145. No cross-reactivity is observed with PAI-2 as tested by ELISA, Westen Blot and Neutralization of inhibitory activity. No reactivity is observed with any other human plasma protein when tested by Western Blot.|
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|
1. Andreasen PA (2007) Current Drug Target 9:1030-1041 2. Loskutoff DJ, et al (1999) Regulation of adhesion by PAI-1. APMIS 107:54-61. 3.Andreasen PA, Kjøller L, Christensen (1997) A review. Int J Cancer 2:1-22. 4. Harbeck N, Kates RE, Look MP (2002) Cancer Res 62:4617-22.5. Grøndahl-Hansen J, et al (1993) Cancer Res 53:2513-2521 6. Nielsen LS, Aet al (1986) Thrombos Haemostas 55:206 212. 7. Lund LR, et al (1988) Mol Cell Endocrinol 60:43 53. 8. Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) J Imm Meth 203:55-65.|